Loading...
•
Jun 30, 2022
DaVita Q2 2022 Earnings Report
DaVita's financial and operating results for Q2 2022 were announced.
Key Takeaways
DaVita Inc. reported consolidated revenues of $2.927 billion, operating income of $433 million, and diluted earnings per share of $2.30 for the quarter ended June 30, 2022. They repurchased 3.9 million shares of their common stock at an average cost of $95.56 per share. Operating cash flow and free cash flow were $188 million and $95 million, respectively.
Consolidated revenues were $2.927 billion.
Operating income was $433 million.
Diluted earnings per share was $2.30.
Operating cash flow and free cash flow were $188 million and $95 million, respectively.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
DaVita provided its 2022 guidance, expecting adjusted operating income between $1.525 billion and $1.675 billion, adjusted diluted net income per share attributable to DaVita Inc. between $7.50 and $8.50, and free cash flow between $850 million and $1.1 billion.
Positive Outlook
- Absence of ballot initiative expenses: $60 million
- Integrated Kidney Care: $0 - $25 million
- Treatment volume growth: ($25) - $125 million
- Revenue per treatment growth: $200 - $250 million
- Cost savings initiatives: $125 - $175 million
Challenges Ahead
- Labor pressure and inflation: ($275) - ($225) million
- The widespread impact of the COVID-19 pandemic continues to generate significant risk and uncertainty.
- Future results could vary materially from the guidance provided.
- Guidance for operating income or diluted net income per share attributable to DaVita Inc. on a basis consistent with United States generally accepted accounting principles (GAAP) is not provided.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...